Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Market Cap	1.36B +11.6%
Revenue (ttm)	63.74M +3.1%
Net Income	-120.05M
EPS	-0.33
Shares Out	389.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,600
Open	3.500
Previous Close	3.700
Day's Range	3.500 - 3.500
52-Week Range	2.500 - 5.250
Beta	-0.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 127
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2563

Financial Performance

In 2025, HKG:2563's revenue was 33.36 million, a decrease of -53.57% compared to the previous year's 71.87 million. Losses were -131.44 million, -8.58% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error